



Alder Biopharmaceuticals Inc. Forms Research Collaboration with Seattle Genetics for Production of Antibodies

Seattle, Washington, November 21, 2005—Alder Biopharmaceuticals Inc., an emerging antibody therapeutics company, today announced a collaborative research alliance with Seattle Genetics, Inc. (Nasdaq: SGEN). Under the collaboration, Alder will use its proprietary yeast production system to produce research materials for one of Seattle Genetics' preclinical therapeutic antibodies.

“We are excited to collaborate with a company that has such extensive experience in the field of antibody therapeutics,” said Dr. Randall Schatzman, President and CEO of Alder. “We believe that Alder’s antibody manufacturing technology has the potential to help Seattle Genetics dramatically reduce the time and cost of making antibodies.”

“We look forward to working with Alder as they continue to advance their platform and build upon encouraging early results,” commented Paul Carter, Ph.D., Vice President, Antibody Technologies at Seattle Genetics.

Alder’s unique contribution to the field involves a platform of proprietary antibody technologies that industrializes the approach to developing, selecting and manufacturing antibody therapeutics. Alder’s technologies dramatically accelerate progress to the clinic while at the same time providing an inexpensive and rapid route through product manufacturing.

For more information or to set up a non-disclosure agreement to learn about Alder’s proprietary technologies in more detail, please contact Mark Litton, Chief Business Officer, at (425) 205-2920 or litton@alderbio.com.

About Alder

Founded in January 2004, Alder Biopharmaceuticals uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas, with extensions into certain forms of cancer. Alder’s management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics. The company acquired early funding from the United States Army in June of 2004 to explore the development of new production technologies for humanized antibodies. That early success was followed by seed funding from WRF Capital and other private investors in the Fall of 2004, and Series A financing led by Sevin Rosen Funds and other investors in August 2005. Today the company is actively engaged in developing its own proprietary therapeutics and enabling partners through out-licensing of its technologies. For more information, visit www.alderbio.com.

Media and Industry Inquiries:

Mark Litton

Chief Business Officer, Alder Biopharmaceuticals Inc.
(425) 205-2920
litton@alderbio.com

Investor Relations:

Randall Schatzman, Ph.D.
CEO, Alder Biopharmaceuticals Inc.
(425) 205-2910
schatzman@alderbio.com

© 2005 Alder Biopharmaceuticals, Inc. Data subject to change.